



NCCAM

April 4, 2006

Dr Gervasio A. Lamas M.D.
Principal Investigator
Trial To Assess Chelation Therapy (TACT)

Dear Dr Lamas:

A recent meeting of the Data and Safety Monitoring Board (DSMB) for the NIH-sponsored *Trial to Assess Chelation Therapy (TACT)* was held March 24, 2006. The committee conducted a comprehensive review of the progress of the trial, including the recruitment and follow-up of patients, an evaluation of all adverse events, and the major clinical outcomes thus far in the trial.

We are pleased to report that on the basis of this review, the committee unanimously recommended to the National Center for Complementary and Alternative Medicine and the National Heart, Lung, and Blood Institute that patients continue to be enrolled and followed, and that the study continue to move forward in addressing its primary and secondary aims. The committee did not register any concerns regarding the safety of patients enrolled in the trial.

We hope this information will be helpful to you in your attention to the ethical and regulatory requirements of this important study.

Sincerely,

Howard N. Hodis, MD
Chair, TACT DSMB
Harry J. Bauer and Dorothy Bauer Rawlins Professor of Cardiology
Professor of Medicine and Preventive Medicine
Professor of Molecular Pharmacology and Toxicology
Director, Atherosclerosis Research Unit
Division of Cardiovascular Medicine
Keck School of Medicine
University of Southern California

Jonathan Berman, MD, PhD
Executive Secretary, TACT DSMB
Director, Office of Clinical and Regulatory Affairs
National Center for Complementary and Alternative Medicine
National Institutes of Health